Evaluation of the patient experience of symptomatic adverse events on Phase I clinical trials using...
Evaluation of the patient experience of symptomatic adverse events on Phase I clinical trials using PRO-CTCAE
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Background
Adverse event (AE) reporting in early-phase clinical trials is essential in determining the tolerability of experimental anticancer therapies. The patient-reported outcome version of the CTCAE (PRO-CTCAE) evaluates AE components such as severity and interference in daily life. The aim of this study was to correlate the grade of clinic...
Alternative Titles
Full title
Evaluation of the patient experience of symptomatic adverse events on Phase I clinical trials using PRO-CTCAE
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9596492
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9596492
Other Identifiers
ISSN
0007-0920,1532-1827
E-ISSN
1532-1827
DOI
10.1038/s41416-022-01926-z
